Skip to main content
Livermore
Livermore
ZHEN

Viking Therapeutics, Inc.

VKTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001607678

In the last 90 days, Viking Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 437 institutions reported holding it in 13F filings for Q2 2026, worth $2.96B in total; no superinvestor holds it.

Holders of 5% or more of VKTX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Viking Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of VKTX
HolderLatest formStakeChangeFirst filedLatest filingFiling
FMR LLC13G/A5.10%5.77M shares−3.60 ppfrom 8.70%Apr 10, 20235 filingsNov 5, 2025SEC
Vanguard Capital Management LLC13G5.08%5.88M sharesNewApr 30, 20261 filingApr 30, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

32 Schedule 13D and 13G filings on Viking Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on VKTX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Apr 30, 20262:21 PM ETVanguard Capital Management LLC13G5.08%5.88M sharesNewMar 31, 2026SEC
Mar 27, 20261:53 PM ETVanguard Group Inc13G/A0.00%0 shares–Below 5%Mar 13, 2026SEC
Nov 5, 202511:49 AM ETFMR LLCand 1 other13G/A5.10%5.77M shares−3.60 ppfrom 8.70%Sep 30, 2025SEC
Aug 6, 202512:19 PM ETFMR LLCand 1 other13G/A8.70%9.77M shares−1.30 ppfrom 10.00%Jun 30, 2025SEC
May 12, 202510:43 AM ETFMR LLCand 1 other13G/A10.00%11.2M shares–Mar 31, 2025SEC
Apr 23, 202510:00 AM ETBlackRock, Inc.13G/A4.50%5.03M shares−0.80 ppfrom 5.30%Below 5%Mar 31, 2025SEC
Feb 4, 20253:45 PM ETBlackRock, Inc.13G5.30%5.87M sharesNewDec 31, 2024SEC
Nov 14, 2024Viking Global Investors LPSuperinvestorViking Global Investors13G/AOld format–––SEC
Nov 12, 2024Vanguard Group Inc13G/AOld format–––SEC
Nov 4, 2024Vanguard Group Inc13G/AOld format–––SEC
Oct 18, 2024State Street Corp13G/AOld format–––SEC
Aug 7, 20244:10 PM ETBlackRock Inc.13G/AOld format–––SEC
Feb 14, 2024Viking Global Investors LPSuperinvestorViking Global Investors13G/AOld format–––SEC
Feb 13, 2024Vanguard Group Inc13GOld format–New–SEC
Feb 9, 2024FMR LLC13G/AOld format–––SEC
Jan 26, 202411:49 AM ETBlackRock Inc.13GOld format–––SEC
Jan 24, 2024State Street Corp13G/AOld format–––SEC
Jan 12, 2024Millennium Management LLC13G/AOld format–––SEC
Nov 2, 2023Viking Global Investors LPSuperinvestorViking Global Investors13GOld format–New–SEC
Apr 10, 2023FMR LLC13GOld format–New–SEC
Mar 30, 20234:08 PM ETLigand Pharmaceuticals Inc13D/AOld format–––SEC
Feb 14, 2023ArrowMark Colorado Holdings LLC13G/AOld format–––SEC
Feb 9, 20234:30 PM ETLigand Pharmaceuticals Inc13D/AOld format–––SEC
Feb 3, 2023State Street Corp13G/AOld format–––SEC
Jan 3, 2023Millennium Management LLC13GOld format–New–SEC
Jul 8, 20224:57 PM ETBlackRock Inc.13GOld format–––SEC
Feb 14, 2022ArrowMark Colorado Holdings LLC13G/AOld format–––SEC
Feb 14, 2022State Street Corp13G/AOld format–––SEC
Feb 3, 20224:41 PM ETBlackRock Inc.13G/AOld format–––SEC
Feb 16, 2021ArrowMark Colorado Holdings LLC13G/AOld format–––SEC
Feb 11, 2021State Street Corp13GOld format–New–SEC
Feb 1, 20218:30 AM ETBlackRock Inc.13G/AOld format–––SEC

Form 144: proposed insider sales

17 notices from officers, directors and other affiliates planning to sell Viking Therapeutics, Inc. shares, newest first.

Form 144 notices for VKTX
Filed (ET)SellerShares to sellMarket valuePlanned saleBrokerFiling
Feb 9, 20244:01 PM ETLian BrianOfficer45.0K$1.31MFeb 9, 202410b5-1Oppenheimer & Co IncSEC
Feb 8, 20244:56 PM ETLian BrianOfficer269.1K$6.85MFeb 8, 202410b5-1Oppenheimer & Co IncSEC
Feb 8, 20244:33 PM ETRouan Sarah KathrynDirector25.0K$701.3KFeb 8, 202410b5-1Oppenheimer & Co IncSEC
Jan 31, 20245:32 PM ETLian BrianOfficer85.0K$2.10MJan 31, 202410b5-1Oppenheimer & Co IncSEC
Jan 30, 20244:23 PM ETLian BrianOfficer35.0K$838.3KJan 30, 202410b5-1Oppenheimer & Co IncSEC
Jan 19, 20244:36 PM ETRouan Sarah KathrynDirector30.0K$691.5KJan 19, 202410b5-1Oppenheimer & Co IncSEC
Jan 4, 20248:12 PM ETZante GregOfficer15.0K$261.0KJan 4, 2024Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC
May 16, 20235:36 PM ETRowland Charles A JrDirector40.0K$1.00MMay 16, 2023Oppenheimer & Co IncSEC
May 16, 20234:39 PM ETMacartney LawsonOfficer16.0K$384.0KMay 16, 2023Oppenheimer & Co IncSEC
May 1, 20231:48 PM ETLian BrianOfficer45.0K$1.01MMay 1, 2023Oppenheimer & Co IncSEC
Apr 24, 20234:48 PM ETMacartney LawsonOfficer16.0K$352.1KApr 24, 202310b5-1Oppenheimer & Co IncSEC
Apr 19, 20234:56 PM ETLian BrianOfficer35.0K$750.8KApr 19, 202310b5-1Oppenheimer & Co IncSEC
Apr 17, 20236:07 PM ETLian BrianOfficer79.3K$2.31MApr 13, 202310b5-1Oppenheimer & Co IncSEC
Apr 17, 20235:50 PM ETLian BrianOfficer155.0K$3.17MApr 17, 202310b5-1Oppenheimer & Co IncSEC
Apr 17, 20235:32 PM ETMacartney LawsonOfficer20.8K$415.7KApr 17, 202310b5-1Oppenheimer & Co IncSEC
Apr 17, 20235:25 PM ETZante GregOfficer7.50K$150.0KApr 17, 2023Oppenheimer & Co IncSEC
Apr 17, 20235:09 PM ETMancini MariannaOfficer12.5K$250.0KApr 17, 2023Oppenheimer & Co IncSEC